David Lewis
Stock Analyst at Morgan Stanley
(2.78)
# 1,784
Out of 4,840 analysts
270
Total ratings
67.18%
Success rate
9.44%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $117 → $127 | $131.30 | -3.27% | 24 | Apr 17, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $321.50 | -6.69% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $171.38 | +60.46% | 23 | Oct 11, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $84.51 | +7.68% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $750 → $720 | $17.95 | +3,911.14% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $30.12 | +232.01% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $124.25 | -87.93% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $3.11 | +864.63% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $54.28 | +38.17% | 11 | Feb 3, 2022 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $42 → $45 | $16.72 | +169.14% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $66.06 | -9.17% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $58.96 | +39.08% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $120.78 | +256.85% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $80.68 | +90.88% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $18.39 | +117.57% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $74.99 | +80.02% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $376.62 | -25.65% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $539.54 | -47.18% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $6.53 | +190.96% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $142.69 | -34.12% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $86.52 | -8.69% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $92.64 | +94.30% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $152.94 | +22.27% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $12.31 | +265.56% | 5 | Dec 15, 2020 |
Abbott Laboratories
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $117 → $127
Current: $131.30
Upside: -3.27%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $321.50
Upside: -6.69%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $171.38
Upside: +60.46%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $84.51
Upside: +7.68%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $750 → $720
Current: $17.95
Upside: +3,911.14%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $30.12
Upside: +232.01%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $124.25
Upside: -87.93%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $3.11
Upside: +864.63%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $54.28
Upside: +38.17%
Envista Holdings
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $16.72
Upside: +169.14%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $66.06
Upside: -9.17%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $58.96
Upside: +39.08%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $120.78
Upside: +256.85%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $80.68
Upside: +90.88%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $18.39
Upside: +117.57%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $74.99
Upside: +80.02%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $376.62
Upside: -25.65%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $539.54
Upside: -47.18%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $6.53
Upside: +190.96%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $142.69
Upside: -34.12%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $86.52
Upside: -8.69%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $92.64
Upside: +94.30%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $152.94
Upside: +22.27%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $12.31
Upside: +265.56%